0001599901-24-000123.txt : 20240805
0001599901-24-000123.hdr.sgml : 20240805
20240805091153
ACCESSION NUMBER: 0001599901-24-000123
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240801
FILED AS OF DATE: 20240805
DATE AS OF CHANGE: 20240805
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moriarty John B
CENTRAL INDEX KEY: 0001564621
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39321
FILM NUMBER: 241173291
MAIL ADDRESS:
STREET 1: ALEXION PHARMACEUTICALS
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Avidity Biosciences, Inc.
CENTRAL INDEX KEY: 0001599901
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461336960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-401-7900
MAIL ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity Biosciences LLC
DATE OF NAME CHANGE: 20161227
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity NanoMedicines LLC
DATE OF NAME CHANGE: 20140211
4
1
wk-form4_1722863507.xml
FORM 4
X0508
4
2024-08-01
0
0001599901
Avidity Biosciences, Inc.
RNA
0001564621
Moriarty John B
C/O AVIDITY BIOSCIENCES, INC.
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO
CA
92121
0
1
0
0
Chief Legal Officer
0
Common Stock
2024-08-01
4
A
0
25000
0
A
25000
D
Stock Option (Right to Buy)
44.57
2024-08-01
4
A
0
160000
0
A
2034-07-31
Common Stock
160000
160000
D
Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of August 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
1/4th of the total number of shares subject to the options shall vest on the first anniversary of August 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.
/s/ Michael F. MacLean, Attorney-in-Fact
2024-08-05